跳转至内容
Merck

M9929

Sigma-Aldrich

甲氨蝶呤

meets USP testing specifications

别名:

甲氨蝶呤 水合物, 对-[(2,4-二氨基喋啶-6)-N-甲基甲氨基]苯甲酰谷氨酸 水合物, L-氨甲喋呤 水合物, MTX 水合物, 氟安定 水合物, 氨甲叶酸 水合物, 氨甲喋呤 水合物

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H22N8O5 · xH2O
分子量:
454.44 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
12352005
PubChem物質ID:
NACRES:
NA.21

生物源

synthetic

品質等級

agency

USP/NF
meets USP testing specifications

化驗

98.0-102.0%

形狀

powder

儲存條件

(Tightly closed. Dry. Keep in a well-ventilated place. )

技術

activity assay: suitable
cell based assay: suitable

雜質

≤0.1% Residue on ignition (Ash)
≤12.0% water (Karl Fischer)

顏色

yellow to orange-yellow

mp

185-204 °C (365 - 399 °F)

溶解度

water: insoluble

抗生素活性譜

parasites

應用

advanced drug delivery
metabolomics
microbiology

作用方式

DNA synthesis

儲存溫度

−20°C

SMILES 字串

[H]O[H].CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);1H2/t13-;/m0./s1

InChI 密鑰

FPJYMUQSRFJSEW-ZOWNYOTGSA-N

正在寻找类似产品? 访问 产品对比指南

應用

二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。也显示免疫抑制作用,如类风湿关节炎。
二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。还可有效治疗耐甲氧嘧啶的 间日 疟原虫。

生化/生理作用

甲氨蝶呤是一种二氢叶酸还原酶(DHFR)的变构抑制剂,DHFR是一种催化二氢叶酸转化为四氢叶酸的酶。 由于嘌呤和嘧啶的合成需要四氢叶酸,甲氨蝶呤处理会抑制DNA和RNA的合成。

其他說明

如需了解生化试剂系列的更多信息,请填写此表

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Acharya Balkrishna et al.
Scientific reports, 9(1), 8025-8025 (2019-05-31)
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that affects joints of hands and feet and introduces injury in secondary organs such as cardiac tissue. In the present study, we induced RA in male Balb/c mice (CAIA) using collagen-antibody
Asma Achek et al.
EBioMedicine, 52, 102645-102645 (2020-02-06)
TLRs are some of the actively pursued drug-targets in immune disorders. Owing to a recent surge in the cognizance of TLR structural biology and signalling pathways, numerous therapeutic modulators, ranging from low-molecular-weight organic compounds to polypeptides and nucleic acid agents
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Methotrexate: new uses for an old drug.
Philip J Hashkes et al.
The Journal of pediatrics, 164(2), 231-236 (2013-11-30)

商品

Separation of Methotrexate (MTX)-PG; Methotrexate (MTX)-PG2; Methotrexate (MTX)-PG3 ; Methotrexate (MTX)-PG4; Methotrexate (MTX)-PG5; Methotrexate (MTX)-PG6; Methotrexate (MTX)-PG7

Separation of Methotrexate (MTX)-PG; Methotrexate (MTX)-PG2; Methotrexate (MTX)-PG3 ; Methotrexate (MTX)-PG4; Methotrexate (MTX)-PG5; Methotrexate (MTX)-PG6; Methotrexate (MTX)-PG7

This article reviews some of our newest and most innovative technologies and their specific applications toward cancer research. It describes how complex the disease of cancer is, and how difficult it is to identify one topic that is completely unrelated to any other.

This issue of Biofiles reviews some of our newest and most innovative technologies and their specific applications toward cancer research. In preparing this issue of Biofiles, one is reminded how complex the disease of cancer is, and how difficult it is to identify one topic that is completely unrelated to any other.

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门